EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial

Xuefeng Ren, Wei Hu, Xiaobin Deng, Rong Ma, Fang Pei, Xushen Chen iD, Xuemei Wang, Jixin Tang, Yan Lai, Shangming Pan, Zhiyong Zhong, Sheng Fu und 10 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70275 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Xuefeng Ren und 21 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd., Zhuhai, Guangdong, China. Hauptthemen laut MEDLINE: Cadmium Poisoning, Chelating Agents, Antidotes, Butyrates. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cadmium exposure causes serious health consequences; however, there is no clinically approved antidote for cadmium poisoning. This Phase 1a/1b trial aimed to investigate safety, tolerability, and pharmacokinetics of Sodium (S)‐2‐(dithiocarboxylato((2S,3R,4R,5R)‐2,3,4,5,6‐pentahydroxyhexyl) amino)‐4‐(methylthio) butanoate (GMDTC), a novel chelating agent proved to eliminate cadmium through renal glucose transporters. This first‐in‐human study included two phases. Phase 1a was a randomized, double‐blind, single‐center, single‐dose, dose escalation trial, in which 78 eligible healthy participants aged 18–65 years were assigned to cohorts receiving GMDTC (250, 500, 850, 1200, 1600, or 2000 mg) or placebo. Thereafter, Phase 1b randomized 30 participants with elevated urinary cadmium into three groups (500, 1000, or 2000 mg GMDTC), who received daily injections for 3 consecutive days, with placebo controls included in each group. During the trial, safety and tolerability were monitored for 72 hour following administration. The primary endpoints included dose‐limiting toxicity, urinary cadmium excretion, pharmacokinetic parameters, and efficacy of GMDTC. In Phase 1a, 76 participants completed the study. No dose‐limiting toxicities were observed, and 169 adverse events were recorded across all cohorts, with no apparent dose‐related pattern or serious safety concerns. GMDTC exhibited dose‐proportional pharmacokinetics, with a half‐life of 1.25–2.63 hour, and urinary cadmium excretion increased dose‐dependently within 24 hour after treatment. In Phase 1b, GMDTC significantly increased 24‐hour urinary cadmium excretion, which positively correlated with the administered dose. GMDTC was well tolerated at doses up to 2000 mg, with no serious adverse events or dose‐limiting toxicities. These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cadmium PoisoningChelating AgentsAntidotesButyratesHumansAdultMaleFemaleMiddle AgedDouble-Blind MethodDose-Response Relationship, DrugYoung AdultAdolescentAgedCadmium

Substanzen

Chelating AgentsCadmiumAntidotesButyrates

Autor:innen und Institutionen

  • Guangdong Jianersheng Pharmaceutical Technology Co., Ltd., Zhuhai, Guangdong, China.
  • School of Public Health, Zhejiang Chinese Medical University, Zhejiang, Hangzhou, China.
  • Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha, Hunan, China.
  • School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Research Center of Occupational Medicine, Peking University Third Hospital, Beijing, China.
  • Department of Psychiatry and Behavioral Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen, China.

ORCID-Profile: Xushen Chen, Xiaojiang Tang

Zitieren

APA

Ren, X., Hu, W., Deng, X., Ma, R., Pei, F., Chen, X., Wang, X., Tang, J., Lai, Y., Pan, S., Zhong, Z., Fu, S., Yuan, H., Yuan, J., Huang, C., Zeng, Y., Ying, X., Dong, G., Zhang, J., …, & Tang, X. (2026). Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70275

Vancouver

Ren X, Hu W, Deng X, Ma R, Pei F, Chen X, et al. Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70275

BibTeX
@article{Ren2026,
  author = {Ren, Xuefeng and Hu, Wei and Deng, Xiaobin and Ma, Rong and Pei, Fang and Chen, Xushen and Wang, Xuemei and Tang, Jixin and Lai, Yan and Pan, Shangming and Zhong, Zhiyong and Fu, Sheng and Yuan, Huamin and Yuan, Juan and Huang, Chuntao and Zeng, Yuan and Ying, Xiaodong and Dong, Guanghui and Zhang, Jinxin and Zhao, Jinyuan and Lin, Kangguang and Tang, Xiaojiang},
  title = {Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70275}
}
Kostenlos starten →